Breast cancer vaccine HER-2/neu (GlaxoSmithKline)

N/A

Report date: 2022/10/14 20:00:43

Base Information

Drug NameBreast cancer vaccine HER-2/neu (GlaxoSmithKline)
Drug Alias NameHER-2/neu peptide vaccine (GlaxoSmithKline)乳腺癌Her-2/neu肽疫苗（葛兰素史克）
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A